These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 8558518)
1. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. Robl JA; Cimarusti MP; Simpkins LM; Brown B; Ryono DE; Bird JE; Asaad MM; Schaeffer TR; Trippodo NC J Med Chem; 1996 Jan; 39(2):494-502. PubMed ID: 8558518 [TBL] [Abstract][Full Text] [Related]
2. Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides. Robl JA; Sulsky R; Sieber-McMaster E; Ryono DE; Cimarusti MP; Simpkins LM; Karanewsky DS; Chao S; Asaad MM; Seymour AA; Fox M; Smith PL; Trippodo NC J Med Chem; 1999 Jan; 42(2):305-11. PubMed ID: 9925736 [TBL] [Abstract][Full Text] [Related]
3. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458 [TBL] [Abstract][Full Text] [Related]
4. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637 [TBL] [Abstract][Full Text] [Related]
5. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors. Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427 [TBL] [Abstract][Full Text] [Related]
6. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Robl JA; Sun CQ; Stevenson J; Ryono DE; Simpkins LM; Cimarusti MP; Dejneka T; Slusarchyk WA; Chao S; Stratton L; Misra RN; Bednarz MS; Asaad MM; Cheung HS; Abboa-Offei BE; Smith PL; Mathers PD; Fox M; Schaeffer TR; Seymour AA; Trippodo NC J Med Chem; 1997 May; 40(11):1570-7. PubMed ID: 9171867 [TBL] [Abstract][Full Text] [Related]
7. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682 [TBL] [Abstract][Full Text] [Related]
8. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857 [TBL] [Abstract][Full Text] [Related]
9. Screening of selected basidiomycetes for inhibitory activity on neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE). Melzig MF; Pieper S; Siems WE; Heder G; Bóttger A; Liberra K; Lindequist U Pharmazie; 1996 Jul; 51(7):501-3. PubMed ID: 8774843 [TBL] [Abstract][Full Text] [Related]
10. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes. Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. French JF; Flynn GA; Giroux EL; Mehdi S; Anderson B; Beach DC; Koehl JR; Dage RC J Pharmacol Exp Ther; 1994 Jan; 268(1):180-6. PubMed ID: 8301555 [TBL] [Abstract][Full Text] [Related]
12. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017 [TBL] [Abstract][Full Text] [Related]
13. New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11. Fink CA; Qiao Y; Berry CJ; Sakane Y; Ghai RD; Trapani AJ J Med Chem; 1995 Dec; 38(26):5023-30. PubMed ID: 8544178 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of metallopeptidases by flavonoids and related compounds. Bormann H; Melzig MF Pharmazie; 2000 Feb; 55(2):129-32. PubMed ID: 10723772 [TBL] [Abstract][Full Text] [Related]
15. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme. Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404 [TBL] [Abstract][Full Text] [Related]
16. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme. Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors. Olimpieri F; Tambaro S; Fustero S; Lazzari P; Sanchez-Roselló M; Pani L; Volonterio A; Zanda M Bioorg Med Chem Lett; 2009 Aug; 19(16):4715-9. PubMed ID: 19596577 [TBL] [Abstract][Full Text] [Related]
18. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat. Sulpizio AC; Pullen MA; Edwards RM; Brooks DP J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834 [TBL] [Abstract][Full Text] [Related]
19. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme. Trapani AJ; Beil ME; Bruseo CW; Savage P; Firooznia F; Jeng AY J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S211-5. PubMed ID: 15838282 [TBL] [Abstract][Full Text] [Related]
20. Metabolism of bradykinin by peptidases in the lung. Dragović T; Igić R; Erdös EG; Rabito SF Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1491-6. PubMed ID: 8389109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]